Fidelity International’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$526M Buy
12,332,054
+9,117,938
+284% +$495M 0.38% 60
2026
Q1
$202M Sell
3,214,116
-1,543,963
-32% -$124M 0.16% 150
2025
Q4
$454M Buy
4,758,079
+99,580
+2% +$9.76M 0.34% 74
2025
Q3
$455M Sell
4,658,499
-220,447
-5% -$22.8M 0.36% 78
2025
Q2
$524M Sell
4,878,946
-835,657
-15% -$84.6M 0.45% 56
2025
Q1
$576M Sell
5,714,603
-2,180,958
-28% -$220M 0.55% 49
2024
Q4
$705M Sell
7,895,561
-424,779
-5% -$37.4M 0.66% 35
2024
Q3
$697M Buy
8,320,340
+922,778
+12% +$72.7M 0.63% 38
2024
Q2
$570M Buy
7,397,562
+1,788,449
+32% +$131M 0.56% 42
2024
Q1
$384M Sell
5,609,113
-335,633
-6% -$21.6M 0.38% 72
2023
Q4
$344M Buy
5,944,746
+80,534
+1% +$4.3M 0.36% 74
2023
Q3
$310M Sell
5,864,212
-1,340,109
-19% -$70.3M 0.36% 77
2023
Q2
$390M Sell
7,204,321
-1,589,254
-18% -$83M 0.44% 60
2023
Q1
$440M Sell
8,793,575
-22,939
-0.3% -$1.08M 0.5% 51
2022
Q4
$408M Buy
8,816,514
+750,298
+9% +$32.5M 0.49% 50
2022
Q3
$312M Buy
8,066,216
+133,568
+2% +$5.36M 0.4% 64
2022
Q2
$296M Buy
7,932,648
+84,599
+1% +$3.44M 0.35% 75
2022
Q1
$348M Buy
7,848,049
+847,580
+12% +$36.7M 0.36% 77
2021
Q4
$297M Buy
7,000,469
+794,032
+13% +$33.4M 0.31% 82
2021
Q3
$269M Buy
6,206,437
+2,176,240
+54% +$96.3M 0.3% 83
2021
Q2
$172M Buy
4,030,197
+657,880
+20% +$27.7M 0.19% 141
2021
Q1
$130M Buy
3,372,317
+295,203
+10% +$11.2M 0.15% 167
2020
Q4
$111M Buy
3,077,114
+85,545
+3% +$3.08M 0.14% 180
2020
Q3
$114M Sell
2,991,569
-127,095
-4% -$4.9M 0.14% 170
2020
Q2
$109M Buy
3,118,664
+737,366
+31% +$26.6M 0.15% 164
2020
Q1
$77.7M Sell
2,381,298
-1,929,624
-45% -$75.4M 0.13% 170
2019
Q4
$195M Buy
4,310,922
+410,845
+11% +$17.2M 0.27% 96
2019
Q3
$159M Buy
3,900,077
+786,656
+25% +$33.3M 0.24% 110
2019
Q2
$134M Buy
3,113,421
+270,213
+10% +$10.4M 0.2% 134
2019
Q1
$109M Buy
2,843,208
+341,571
+14% +$13M 0.17% 147
2018
Q4
$88.4M Sell
2,501,637
-456,062
-15% -$16.5M 0.16% 164
2018
Q3
$114M Buy
2,957,699
+252,421
+9% +$8.82M 0.17% 156
2018
Q2
$88.5M Buy
2,705,278
+73,138
+3% +$2.21M 0.13% 180
2018
Q1
$71.9M Buy
2,632,140
+201,519
+8% +$5.48M 0.2% 136
2017
Q4
$60.3M Buy
2,430,621
+794,172
+49% +$21.9M 0.17% 143
2017
Q3
$47.7M Buy
1,636,449
+406,257
+33% +$11.2M 0.14% 158
2017
Q2
$34.1M Buy
+1,230,192
New +$32.6M 0.1% 185
2014
Q2
Sell
-285,400
Closed -$3.86M 503
2014
Q1
$3.86M Buy
285,400
+217,200
+318% +$2.85M 0.01% 443
2013
Q4
$820K Sell
68,200
-8,500
-11% -$100K ﹤0.01% 481
2013
Q3
$900K Sell
76,700
-10,000
-12% -$108K ﹤0.01% 490
2013
Q2
$804K Buy
+86,700
New +$735K ﹤0.01% 449

Other funds holding BSX

Fidelity International's BSX Position: Q2 2026 in Review

Fidelity International increased its Boston Scientific (BSX) stake by 284% in Q2 2026, buying an estimated $495M and bringing the position to 12,332,054 shares worth $526M. The position accounts for 0.38% of the portfolio, ranked #60.

Fidelity International first reported a position in BSX in Q2 2013 and has held it in 41 quarters since. The position peaked at $705M in Q4 2024. 1,209 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Fidelity International held 12,332,054 shares of Boston Scientific worth $526M as of Q2 2026.
  • Fidelity International bought 9,117,938 Boston Scientific shares in Q2 2026, an estimated $495M.
  • Boston Scientific made up 0.38% of Fidelity International's portfolio in Q2 2026, its #60 holding.
  • Fidelity International first reported a position in Boston Scientific in Q2 2013 and has held it in 41 quarters since.
  • Fidelity International's Boston Scientific position peaked at $705M in Q4 2024.
  • 1,209 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.